JPMorgan Chase & Co. Reiterates “Neutral” Rating for Novo Nordisk A/S (NOVOB)

Novo Nordisk A/S (SWX:NOVOB)‘s stock had its “neutral” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a research report issued on Thursday.

Separately, Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Wednesday, October 10th.

Novo Nordisk A/S stock opened at €47.79 ($55.57) on Thursday. Novo Nordisk A/S has a 1-year low of €33.43 ($38.87) and a 1-year high of €56.35 ($65.52).

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply